Workflow
LifeStance Reports Third Quarter 2025 Results
Globenewswire· 2025-11-06 19:00
SCOTTSDALE, Ariz., Nov. 06, 2025 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (Nasdaq: LFST), one of the nation’s largest providers of outpatient mental healthcare, today announced financial results for the third quarter ended September 30, 2025. (All results compared to prior-year comparative period, unless otherwise noted)Q3 2025 Highlights and FY 2025 Outlook Revenue of $363.8 million increased 16% compared to revenue of $312.7 millionClinician base increased 11% to 7,996 clinicians, a sequential ne ...
Millicom (Tigo) Q3 2025 Earnings Release
Globenewswire· 2025-11-06 19:00
Millicom (Tigo) Q3 2025 Earnings Release Luxembourg, November 6, 2025 – Millicom is pleased to announce its third quarter 2025 results. Please find below links to the Q3 2025 Earnings Release and IAS 34 Interim Condensed Consolidated Financial Statements. Q3 2025 Highlights* Revenue $1.42 billion Operating profit $390 million, and record Adjusted EBITDA $695 million Net profit attributable to company owners $195 million, including approximately $138 million net profit from the closure of infrastructure tr ...
Ducommun Incorporated Reports Third Quarter 2025 Results
Globenewswire· 2025-11-06 19:00
Record Quarterly Revenue and Gross MarginsCOSTA MESA, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Ducommun Incorporated (NYSE: DCO) (“Ducommun” or the “Company”) today reported results for its third quarter ended September 27, 2025. Third Quarter 2025 Recap Net Revenue was $212.6 million, an increase of 6% over Q3 2024Gross margin of 26.6%, year-over-year growth of 40 bpsNet loss of $64.4 million or $4.30 per share, or 30.3% of revenueNon-GAAP adjusted net income of $15.2 million (increase of 2% year-over-yea ...
KBR Selected to Deliver Detailed Engineering Design for the Gas Growth Integrated Project Operated by TotalEnergies in Iraq
Globenewswire· 2025-11-06 19:00
项目核心信息 - KBR公司获得ENKA授予的伊拉克Associated Gas Upstream项目二期详细工程设计服务合同 [1] - 该项目是道达尔能源及其合作伙伴运营的Gas Growth Integrated Project的一部分 [1] - 项目计划于2028年启动,旨在处理Ratawi油田的石油和伴生气,将石油产能提升至21万桶/日,天然气产能提升至1.54亿标准立方英尺/日 [3] - 项目目标包括消除常规燃烧,支持伊拉克向低碳能源转型 [3] 公司角色与能力 - KBR将利用其全球工程中心提供多学科详细工程设计服务,支持ENKA执行中心处理设施的工程、采购、供应、建设和调试范围 [3] - 此次授标是基于KBR成功交付同一开发项目的前端工程设计,体现了公司与道达尔能源和ENKA的长期合作关系 [2] - KBR在伊拉克已有超过40年的服务经验,在气体处理、碳减排和能源转型技术方面具有专业能力 [4] - 公司拥有约3.7万名员工,在29个国家开展业务 [5] 项目战略意义 - 该项目被视为伊拉克能源未来的战略里程碑,结合了气体回收、发电、油田再开发和可再生能源投资 [4] - 将支持伊拉克实现能源生产自给自足并改善环境绩效的目标 [4] - GGIP项目旨在通过开发伊拉克自然资源来改善国家电力供应,是一个四合一的多能源项目 [6] - 项目内容包括回收目前在南伊拉克三个油田燃烧的天然气,为发电厂供电,支持Ratawi油田再开发,建设1GWac太阳能发电厂和海水处理厂 [6]
QuantaSing Group Limited Announces Results of Extraordinary General Meeting
Globenewswire· 2025-11-06 19:00
BEIJING, Nov. 06, 2025 (GLOBE NEWSWIRE) -- QuantaSing Group Limited (NASDAQ: QSG) ("QuantaSing" or the "Company"), a pop toy company dedicated to creating beloved collectibles and trend-defining experiences, today announced the results of its extraordinary general meeting held on November 6, 2025 for the changes of its company name and ticker symbol. At the meeting, the Company’s shareholders approved the following proposals by special resolutions: The change of the Company’s name from “QuantaSing Group Lim ...
CLEAR Announces Third Quarter 2025 Financial Results
Globenewswire· 2025-11-06 19:00
NEW YORK, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Clear Secure, Inc. (NYSE: YOU), the secure identity company, has released financial results for the third quarter of fiscal year of 2025 on its Investor Relations website at https://ir.clearme.com. Third Quarter Financial Highlights(percentage change is expressed as year-over-year, unless otherwise specified) Revenue of $229.2 million was up 15.5%; Total Bookings of $260.1 million were up 14.3%Operating income of $52.6 million, representing a 23.0% Operating incom ...
Privia Health Reports Third Quarter 2025 Financial Results
Globenewswire· 2025-11-06 19:00
Very Strong Third Quarter and Year-to-Date Performance Across the BusinessNet Income +94.1% and Adjusted EBITDA +61.6% compared to 3Q’24Implemented Providers +13.1% and Practice Collections +27.1% compared to 3Q’24FY’25 Guidance Raised Above High End for All Key Operating and Financial Metrics ARLINGTON, Va., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (Nasdaq: PRVA) today announced financial results for the third quarter ended September 30, 2025. Third Quarter Performance For the Three Mo ...
First Advantage Reports Third Quarter 2025 Results
Globenewswire· 2025-11-06 19:00
Delivers Strong Third Quarter Results and Refines Full Year 2025 GuidanceThird Quarter 2025 Highlights1 Revenues of $409.2 millionNet Income of $2.6 million, a net income margin of 0.6%, includes $6.3 million of expenses related to the acquisition of Sterling Check Corp. (“Sterling”) and related integration, and $41.7 million of Sterling acquisition depreciation and amortizationAdjusted Net Income of $52.3 millionAdjusted EBITDA of $118.5 million; Adjusted EBITDA Margin of 29.0%GAAP Diluted Net Income Per S ...
Arhaus Reports Third Quarter 2025 Financial Results
Globenewswire· 2025-11-06 19:00
BOSTON HEIGHTS, Ohio, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Arhaus, Inc. (“Arhaus” or the “Company”) (NASDAQ: ARHS), a growing lifestyle brand and omni-channel retailer of premium artisan-crafted home furnishings, reported third quarter 2025 results for the period ended September 30, 2025. Third Quarter 2025 Highlights Net revenue increased 8.0% to $345 million, compared to the third quarter of 2024Gross margin increased 8.4% to $133 million, compared to the third quarter of 2024Selling, general and administrat ...
4DMT Announces Positive Long-Term Data from Phase 1/2 PRISM Clinical Trial in Wet AMD Supporting 4D-150’s Potential as a Backbone Therapy with Consistent and Durable Benefit over Multiple Years
Globenewswire· 2025-11-06 19:00
4D-150 demonstrated consistent and durable benefit across all three patient cohorts as evidenced by maintenance of visual acuity, control of retinal anatomy and reduction of treatment burden at all time points with up to 2 years of follow-upStrong dose response in favor of Phase 3 dose (3E10 vg/eye) continues to be demonstrated4D-150 continues to be well tolerated with no new safety or intraocular inflammation findings, consistent with previous updates, with up to 3.5 years of follow-up4FRONT-1 Phase 3 enro ...